Completed PHASE3 INTERVENTIONAL NCT00002542

Tamoxifen in Treating Women With High-Risk Breast Cancer

Double-Blind Randomized Trial of Tamoxifen Versus Placebo in Patients With Node Positive or High Risk Node Negative Breast Cancer Who Have Completed CMF, CEF, or AC Adjuvant Chemotherapy

Sponsor: NCIC Clinical Trials Group

Conditions Breast Cancer

Interventions CMF regimen cyclophosphamide doxorubicin hydrochloride epirubicin hydrochloride fluorouracil methotrexate radiation therapy tamoxifen citrate

Updated 7 times since 2017 Last updated: Mar 30, 2020 Started: Jul 20, 1993 Primary completion: Mar 7, 2007 Completion: Jan 11, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Breast Cancer, this trial is completed. The trial is conducted by NCIC Clinical Trials Group and has accumulated 7 data snapshots since 1993. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
May 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — May 2020 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 1993

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NCIC Clinical Trials Group

Data source: Canadian Cancer Trials Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barrie, Canada , Brampton, Canada , Calgary, Canada , Charlottetown, Canada , Edmonton, Canada , Greater Sudbury, Canada , Halifax, Canada , Hamilton, Canada , Joliette, Canada , Kingston, Canada and 24 more locations